166 related articles for article (PubMed ID: 10493397)
1. Pathophysiology of L-dopa-induced dyskinesias.
Bédard PJ; Blanchet PJ; Lévesque D; Soghomonian JJ; Grondin R; Morissette M; Goulet M; Calon F; Falardeau P; Gomez-Mancilla B; Doucet JP; Robertson GS; DiPaolo T
Mov Disord; 1999; 14 Suppl 1():4-8. PubMed ID: 10493397
[No Abstract] [Full Text] [Related]
2. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
Guigoni C; Dovero S; Aubert I; Li Q; Bioulac BH; Bloch B; Gurevich EV; Gross CE; Bezard E
Eur J Neurosci; 2005 Jul; 22(1):283-7. PubMed ID: 16029219
[TBL] [Abstract][Full Text] [Related]
3. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
4. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
Darmopil S; Muñetón-Gómez VC; de Ceballos ML; Bernson M; Moratalla R
Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311
[TBL] [Abstract][Full Text] [Related]
6. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Pavón N; Martín AB; Mendialdua A; Moratalla R
Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
[TBL] [Abstract][Full Text] [Related]
7. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
[TBL] [Abstract][Full Text] [Related]
8. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
[TBL] [Abstract][Full Text] [Related]
9. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
Giorgi M; D'Angelo V; Esposito Z; Nuccetelli V; Sorge R; Martorana A; Stefani A; Bernardi G; Sancesario G
Eur J Neurosci; 2008 Sep; 28(5):941-50. PubMed ID: 18717735
[TBL] [Abstract][Full Text] [Related]
10. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
11. Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesia.
Brotchie JM
Adv Neurol; 1999; 80():71-85. PubMed ID: 10410705
[No Abstract] [Full Text] [Related]
12. Dyskinesias assessment in Phase II studies.
Damier P; Jaillon C; Clavier I; Arnulf I; Bonnet AM; Bejjani BP; Agid Y
Mov Disord; 1999; 14 Suppl 1():54-9. PubMed ID: 10493404
[No Abstract] [Full Text] [Related]
13. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
Guigoni C; Doudnikoff E; Li Q; Bloch B; Bezard E
Neurobiol Dis; 2007 May; 26(2):452-63. PubMed ID: 17350277
[TBL] [Abstract][Full Text] [Related]
14. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Encarnacion EV; Hauser RA
Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
[TBL] [Abstract][Full Text] [Related]
15. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
16. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
Lundblad M; Picconi B; Lindgren H; Cenci MA
Neurobiol Dis; 2004 Jun; 16(1):110-23. PubMed ID: 15207268
[TBL] [Abstract][Full Text] [Related]
17. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.
Marek K; Jennings D; Seibyl J
Ann Neurol; 2003; 53 Suppl 3():S160-6; discussion S166-9. PubMed ID: 12666107
[No Abstract] [Full Text] [Related]
18. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Zhang H; Ma L; Wang F; Chen J; Zhen X
Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
[TBL] [Abstract][Full Text] [Related]
19. [Dopamine agonists in the therapy of parkinson syndrome].
Kapfhammer HP; Rüther E
Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
[No Abstract] [Full Text] [Related]
20. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Fox SH; Chuang R; Brotchie JM
Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
